SG Americas Securities LLC Has $222,000 Holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA)

SG Americas Securities LLC increased its stake in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 62.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 116,771 shares of the biopharmaceutical company’s stock after purchasing an additional 44,806 shares during the period. SG Americas Securities LLC owned approximately 0.05% of Akebia Therapeutics worth $222,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in AKBA. JPMorgan Chase & Co. raised its stake in Akebia Therapeutics by 10.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 98,546 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 9,662 shares during the period. Franklin Resources Inc. acquired a new position in shares of Akebia Therapeutics in the 3rd quarter valued at approximately $221,000. Barclays PLC increased its stake in Akebia Therapeutics by 276.1% during the 3rd quarter. Barclays PLC now owns 273,085 shares of the biopharmaceutical company’s stock worth $360,000 after purchasing an additional 200,482 shares in the last quarter. Geode Capital Management LLC increased its stake in Akebia Therapeutics by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 4,754,464 shares of the biopharmaceutical company’s stock worth $6,277,000 after purchasing an additional 218,172 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Akebia Therapeutics in the third quarter valued at approximately $58,000. 33.92% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on AKBA shares. HC Wainwright reaffirmed a “buy” rating and set a $7.50 price target on shares of Akebia Therapeutics in a research report on Thursday, January 23rd. StockNews.com cut Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th.

Akebia Therapeutics Stock Down 0.9 %

NASDAQ:AKBA opened at $2.14 on Friday. Akebia Therapeutics, Inc. has a 12-month low of $0.80 and a 12-month high of $2.48. The firm has a market capitalization of $466.91 million, a price-to-earnings ratio of -9.30 and a beta of 0.74. The stock’s 50 day moving average price is $2.01 and its two-hundred day moving average price is $1.68.

Akebia Therapeutics (NASDAQ:AKBA) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.06). The firm had revenue of $37.43 million during the quarter, compared to the consensus estimate of $45.66 million. During the same quarter last year, the firm earned ($0.08) earnings per share. Equities research analysts expect that Akebia Therapeutics, Inc. will post -0.3 EPS for the current year.

Insider Buying and Selling at Akebia Therapeutics

In other Akebia Therapeutics news, CAO Richard C. Malabre sold 30,202 shares of Akebia Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $2.10, for a total value of $63,424.20. Following the transaction, the chief accounting officer now owns 280,248 shares in the company, valued at $588,520.80. The trade was a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO John P. Butler sold 144,250 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total transaction of $302,925.00. Following the transaction, the chief executive officer now owns 2,604,330 shares of the company’s stock, valued at approximately $5,469,093. This represents a 5.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 280,579 shares of company stock valued at $589,216 in the last quarter. Company insiders own 4.10% of the company’s stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.